Clinical Trial Update: Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of 333369 for partial epilepsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial Epilepsy

Drugs mentioned

• 333369

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Refractory Epilepsy | Phase 2 | Status: COMPLETED